Intradaytrade
$IBO CO-Founder with wide ranging work-experienceDr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
$IBO’S CEO comments on the H.C Wainwright"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
$HEM announcement related to the Stock Options GrantHemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Universal Ibogaine Delivering Excellence The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
Potential aptitude of NCP-01 by Hemostemix Neuropathic pain synNeuropathic pain syndromes can be treated with NCP-01 and its autologous stem cell technology, which can treat disorders of the central and peripheral nervous systems. Spinal cord injury, chronic brainstem injury, traumatic brain injury, and peripheral nerve injury are all examples of traumatic injuries and many more
$IBOGF accord with blue digital media calls for added benefitsBlue Digital will be paid USD 27,000 for a three-month commitment beginning June 13, 2022. Additionally, Blue Digital will get 450,000 company's stock options to purchase common shares of the Company, with an exercise price of $0.10 per share, a three-year term, and one-third vesting at the conclusion of each month of service.
$IBOGF CEO Thoughts on H.C Wainwright.It gives UI great pleasure to announce that Nick Karos, CEO, will speak at the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond. On June 27, 2022, a hybrid online and offline event will take place. "H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
Blue digital media to highlight $IBO narrativeThe UI story will be distributed through numerous platforms and audiences by Blue Digital. The expected outcome is increased knowledge of UI's plans to conduct research into the use of ibogaine as part of a continuum of care for opioid addiction and other addictions.
UI CEO’s thrilled to work with Blue Digital Media"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." Alike Blue Digital Media’s expertise radar